Access to the PPM Journal and newsletters is FREE for clinicians.

Meeting Highlights from ACR Convergence 2020

Meeting Information

November 5-9, 2020

The American College of Rheumatology's annual meeting was held virtually in November 2020. #ACR20

From this Meeting:

New disease-modifying biologics (DMARDs) and evidence regarding steroids, immunizations, and infection screening have led to a need for updated treatment approaches for juvenile idiopathic arthritis (JIA).
Vibeke Strand, MD, and Michael E. Weinblatt, MD, make distinct cases for the use of JAK inhibitors versus TNF inhibitors for the treatment of rheumatoid arthritis in patients refractory to methotrexate.
Experts discuss pharmacotherapy tactics for treating rheumatic disease, including rheumatoid arthritis, in older adults.
Immunological complications of rheumatoid arthritis therapy can make clinical decisions around treatment more difficult. In an ACR 2020 Convergence panel, experts reviewed inflammatory arthritis in the context of immune checkpoint inhibitors, including a look at the safety of the recombinant zoster (shingles) vaccine and cancer tumor response in patients with rheumatic disease.
Rheumatoid arthritis now has many treatment options, allowing providers to tailor therapy to individual patients. However, when patients have chronic comorbidities on top of the disease, or when therapy after therapy fails, decisions about treatment and monitoring can be complex. 3 case examples.
close X